Öz
Giriş: Tüberküloz (TB), Mycobacterium tuberculosis’in neden olduğu bulaşıcı bir hastalıktır. Bacillus Calmette-Guérin, verem için kullanılabilen tek aşıdır. Bununla birlikte, aşı çocukları TB’den etkili bir şekilde koruduğu halde, yetişkinlerdeki etkinliği hala tartışmalıdır. Şu anda TB’yi önlemek için etkili bir aşı bulunmamaktadır. Etkili bir aşı, M. tuberculosis’in makrofajlara yapışmasını önlemek için humoral bağışıklığı tetiklemelidir. Bu bağlamda, B hücresi epitopları aşı geliştirmede önemli bir rol oynayabilir. Bu nedenle, bu çalışma in silico araçlar kullanılarak B hücresi epitoplarını tanımlamayı amaçlamıştır.
Gereç ve Yöntem: Bu çalışmada, B hücresi epitopları, üç yöntemden (yapay sinir ağları, BCPred ve AAP) oluşan iki araç (ABCPred ve BCPREDS) kullanılarak tahmin edildi. Ayrıca, üç tahmin yöntemiyle tahmin edilen epitoplar örtüşme açısından analiz edildi ve analiz için ToxinPred, VaxiJen ve AllerTop sunucuları kullanıldı.
Bulgular: Tüm tahmin yöntemleri kullanılarak toplam 2003 epitop tahmin edildi. Bunlar arasında 80 epitop, örtüşen epitoplar olarak tahmin edildi ve sırasıyla ToxinPred, VaxiJen ve AllerTop araçları kullanılarak 80, 57 ve 29 epitop tarandı.
Sonuç: Mevcut çalışmada tahmin edilen epitopların, M. tuberculosis enfeksiyonuna karşı B-hücresi tepkisine yönelik in vitro ve in vivo analizler kullanılarak doğrulanması gerekmektedir.
Anahtar Kelimeler: Epitoplar, B hücresi, Mycobacterium tuberculosis, aşı
Kaynakça
Raviglione MC, Dye C, Schmidt S, Kochi A, Surveillance WG. Assessment of worldwide tuberculosis control. Lancet. 1997;350:624-29.
Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement, Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country, WHO Global Surveillance and Monitoring Project. JAMA. 1999;282:677-86.
World Health Organization (WHO). Global Tuberculosis Report 2018. World Health Organization. Available from: https://apps.who.int/iris/bitstream/handle/10665/274453/9789241565646-eng.pdf
Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet. 1995;346:1339-45.
Barreto ML, Pereira SM, Ferreira AA. BCG vaccine: efficacy and indications for vaccination and revaccination. J Pediatr. 2006;82:S45-54.
Cooper AM. Cell-mediated immune responses in tuberculosis, Ann Rev Immun. 2009;27:393-422.
Seder RA, Hill AV. Vaccines against intracellular infections requiring cellular immunity. Nature. 2000;406:793.
Achkar M, Jenny-Avital E, Yu X, Burger S, Leibert E, Bilder PW, Almo SC, Casadevall A, Laal S. Antibodies against immunodominant antigens of Mycobacterium tuberculosis in subjects with suspected tuberculosis in the United States compared by HIV status, Clin Vaccine Immunol. 2010;7:384-92.
Steingart KR, Dendukuri N, Henry M, Schiller I, Nahid P, Hopewell PC, Ramsay A, Pai M, Laal S. Performance of purified antigens for serodiagnosis of pulmonary tuberculosis: a meta-analysis. Clin Vaccine Immunol. 2009;16:260-76.
Culkin SJ, Rhinehart-Jones T, Elkins KL. A novel role for B cells in early protective immunity to an intracellular pathogen. Francisella tularensis strain LVS. J Immunol. 1997;158:3277-84.
Langhorne J, Cross C, Seixas E, Li C, Von Der Weid T. A role for B cells in the development of T cell helper function in a malaria infection in mice. Proc Natl Acad Sci. 1998;95:1730-4.
Mastroeni P, Simmons C, Fowler R, Hormaeche CE, Dougan G. Igh-6−/−(B-cell-deficient) mice fail to mount solid acquired resistance to oral challenge with virulent salmonella enterica serovar typhimurium and show impaired th1 t-cell responses to Salmonella antigens. Infect Immun. 2000;68:46-53.
Casadevall A. Antibody-mediated immunity against intracellular pathogens: two-dimensional thinking comes full circle. Infect Immun. 2003;71:4225-8.
Kozakiewicz L, Phuah J, Flynn J, Chan J. The role of B cells and humoral immunity in Mycobacterium tuberculosis infection. Adv Exp Med Biol. 2013;783:225-50
Wahid R, Zafar SJ, McArthur MA, Pasetti MF, Levine MM, Sztein MB. Live oral Salmonella enterica serovar Typhi vaccines Ty21a and CVD 909 induce opsonophagocytic functional antibodies in humans that cross-react with S. Paratyphi A and S. Paratyphi B. Clin. Vaccine Immunol. 2014;21:427-34.
Bowe F, Lavelle EC, McNeela, Hale C, Clare S, Arico B, Giuliani MM, Rae A, Huett A, Rappuoli R, Dougan G Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin. Infect Immun. 2004;72:4052-60.
Khan SA, Waugh C, Rawlinson G, Brumm J, Nilsson K, Gerdts V, Potter A, Polkinghorne A, Beagley K, Timms P. Vaccination of koalas (Phascolarctos cinereus) with a recombinant chlamydial major outer membrane protein adjuvanted with poly I: C, a host defense peptide and polyphosphazine, elicits strong and long lasting cellular and humoral immune responses. Vaccine. 2014;32:5781-6.
Mizutani M, Iyori M, Blagborough AM, Fukumoto S, Funatsu T, Sinden RE, Yoshida S. Baculovirus-vectored multistage Plasmodium vivax vaccine induces both protective and transmission-blocking immunities against transgenic rodent malaria parasites. Infect Immun. 2014;82:4348-57.
Rawool DB, Bitsaktsis C, Li Y, Gosselin DR, Lin Y, Kurkure NV, Metzger DW, Gosselin EJ. Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis. J Immun. 2008;180:5548-57.
Achkar JM, Casadevall A. Antibody-mediated immunity against tuberculosis: implications for vaccine development. Cell Host Microbe. 2013;13:250-62.
Olivares N, Marquina B, Mata-Espinoza D, Zatarain-Barron ZL, PinzónCE, Estrada I, Parada C, Collin M, Rook G, Hernandez-Pando R. The protective effect of immunoglobulin in murine tuberculosis is dependent on IgG glycosylation. Pathog Dis. 2013;69:176-83.
Alvarez N, Otero O, Camacho F, Borrero R, Tirado Y, Puig A, Aguilar A, Rivas C, Cervantes A, Falero-Díaz G, Cádiz A. Passive administration of purified secretory IgA from human colostrum induces protection against Mycobacterium tuberculosis in a murine model of progressive pulmonary infection. BMC Immunol. 2013;14(Suppl 1):S3.
Hamasur B, Haile M, Pawlowski A, Schröder U, Källenius G, Svenson SB. A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab′) 2 fragment prolong survival of mice infected with Mycobacterium tuberculosis. Clin Exp Immunol. 2004;138:30-8.
Kang PB, Azad AK, J. Torrelles JB, Kaufman TM, Beharka A, Tibesar E, DesJardin LE, Schlesinger LS. The human macrophage mannose receptor directs Mycobacterium tuberculosis lipoarabinomannan-mediated phagosome biogenesis. J Exp Med. 2005;202:987-99.
Robbins JB, Schneerson R, Szu SC. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculums. J Infect Dis. 1995;171:1387-98.
Raghuwanshi R, Singh M, Shukla V. Immunoinformatic approaches in epitope prediction for vaccine designing against viral infections. Virol Immunol J. 2018;2:000142.
Mtimet G, Stayoussef M, Yacoubi-Loueslati B. Prediction of the Most probable B cell epitopes from (DnaK) adhesin of Mycobacterium tuberculosis using immunoinformatic tools. Int J Pept Res Ther. 2019;26:1-9.
Schafer JR, Jesdale BM, George JA, Kouttab NM, De Groot AS. Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix. Vaccine. 1998;16:1880-4.
De Groot AS, Bosma A, Chinai N, Frost J, Jesdale BM, Gonzalez MA, Martin W, Saint-Aubin C. From genome to vaccine: in silico predictions, ex vivo verification. Vaccine. 2001;19:4385-95.
Kaufmann SH, Weiner J, von Reyn CF. Novel approaches to tuberculosis vaccine development. Int J Infect Dis. 2017;56:263-7.
Saha S, Raghava CP. Prediction of continuous B‐cell epitopes in an antigen using recurrent neural network. Proteins. 2006;65:40-8.
L‐Manzalawy Y, Dobbs D, Honavar V. Predicting linear B‐cell epitopes using string kernels. J Mol Recognit. 2008;21:243-55.
Chen J, Liu H, Yang J, Chou KC. Prediction of linear B-cell epitopes using amino acid pair antigenicity scale. Amino Acids. 2007;33:423-8.
Gupta S, Kapoor P, Chaudhary K, Gautam A, Kumar R, Raghava P. Open Source Drug Discovery Consortium. In silico approach for predicting toxicity of peptides and proteins. PloS One. 2013;8:e73957.
Zaharieva N, Dimitrov I, Flower DR, Doytchinova I. Immunogenicity prediction by VaxiJen: a ten year overview. J Proteomics Bioinform. 2017;10:298-310.
Dimitrov I, Bangov I, Flower DR, Doytchinova I. AllerTOP v. 2-a server for in silico prediction of allergens. J Mol Model. 2014;20:2278.
Checkley AM, McShane H. Tuberculosis vaccines: progress and challenges. Trends Pharmacol Sci. 2011;32:601-6.
Soria-Guerra RE, Nieto-Gomez R, Govea-Alonso DO, Rosales-Mendoza S. An overview of bioinformatics tools for epitope prediction: implications on vaccine development. J Biomed Inf. 2015;53:405-14.
Rao M, Valentini D, Poiret T, Dodoo E, Parida S, Zumla A, Brighenti S, Maeurer M. B in TB: B cells as mediators of clinically relevant immune responses in tuberculosis. Clin Infect Dis. 2015;61:S225-34.
Mohan M, Sundar K. Genome-wide prediction of human papilloma virus specific t-cell epitopes using a combination of matrix based computational Tools. Int J Pharm Pharm Sci. 2017;9:175-82.
Adhikari UK, Tayebi M, Rahman MM. Immunoinformatics approach for epitope-based peptide vaccine design and active site prediction against polyprotein of emerging oropouche virus. J Immunol Res. 2018:1-22.
Rao BS, Gupta KK, Kumari S, Gupta A, Pujitha K. Conserved HIV wide spectrum antipeptides-a hope for HIV treatment. Adv Tech Biol Med. 2013;1:1.
McKeever TM, Lewis SA, Smith C, Hubbard R. Vaccination and allergic disease: a birth cohort study. Am J Public Health. 2004;94:985-9.
Skjøt RL, Oettinger T, Rosenkrands I, Ravn P, Brock I, Jacobsen S, Andersen P. Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as Immunodominant T-cell antigens. Infect Immun. 2000;68:214-20.
Arend SM, Engelhard AC, Groot G, de Boer K, Andersen P, Ottenhoff TH, van Dissel JT. Tuberculin skin testing compared with T-cell responses to Mycobacterium tuberculosis-specific and nonspecific antigens for detection of latent infection in persons with recent tuberculosis contact. Clin Diagn Lab Immunol. 2001;8:1089-96.
Nair S, Ramaswamy PA, Ghosh S, Joshi DC, Pathak N, Siddiqui I, Sharma P, Hasnain SE, Mande SC, Mukhopadhyay S. The PPE18 of Mycobacterium tuberculosis interacts with TLR2 and activates IL-10 induction in macrophage. J Immun. 2009;183:6269-81.
Babaki MK, Soleimanpour S, Rezaee SA. Antigen 85 complex as a powerful Mycobacterium tuberculosis immunogene: biology, immune-pathogenicity, applications in diagnosis, and vaccine design. Microb Pathog. 2017;112:20-9.
Portal-Celhay C, Tufariello JM, Srivastava S, Zahra A, Klevorn T, Grace PS, Mehra A, Park HS, Ernst JD, Jacobs Jr. WR, Philips JA. Mycobacterium tuberculosis EsxH inhibits ESCRT-dependent CD4+ T-cell activation. Nat Microbiol. 2017;2:16232.
Mehra A, Zahra A, Thompson V, Sirisaengtaksin N, Wells A, Porto M, Köster S, Penberthy K, Kubota Y, Dricot A, Rogan D. Mycobacterium tuberculosis type VII secreted effector EsxH targets host ESCRT to impair trafficking. PLoS Pathog. 2013;9:e1003734.
